BS People: Rajiv Malik

Mylan picks Malik as global President

The US-based Mylan Inc, the third largest generic drug makers in the world, has set its eye on replacing Teva as the industry leader and its strategy for doing so includes the appointment of Rajiv Malik as its global president.

Malik, 50, who served as Mylan’s chief operating officer, will be responsible for the day-to-day global operations of the company.

Malik, who enjoyed 25 years of experience in the global generic pharmaceutical industry, began his research and development career at Ranbaxy Laboratories, rising to head of generics R&D. He also worked with Sandoz where he served as the head of global development and regulatorion.

 

"I am excited to continue to drive forward many of our key strategic initiatives, for instance our commercial launch in India, our biogenerics strategy and other areas of business development," said Malik, on his new role.

In 2005, Malik joined Matrix Labs, which was acquired by Mylan a year later. Mylan which bought 71.5 per cent in Matrix for $736 million retained Malik as CEO.

Malik earned his master's degree in pharmaceutical technology from Punjab University and has more than 60 process patents to his credit. As COO, Malik was responsible for Mylan’s global research and development (R&D) centres, and manufacturing and distribution units. In addition, Malik was responsible for enhancing and rationalising Mylan’s global supply chain and expanded product pipeline.